Parallel Bio has developed an organoid-based immune system platform that combines lymph-node organoids with AI and robotics to model human immune responses at scale. Its Clinical Trial in a Dish offering is being used by pharmaceutical partners to test safety and efficacy of immunotherapies and drugs across diverse human-derived organoids. The company has signed eight pharmaceutical partners, including three Fortune 500 companies, who are testing more than 50 drugs and immunotherapies on the platform. A reported preclinical study with partner Centivax validated broad humoral and T cell responses to its Centi‑Flu universal flu vaccine candidate and supported Centivax’s move to manufacturing for human trials. Parallel Bio plans to use the new capital to scale AI and automation, expand its scientific and engineering team, and support growing pharmaceutical partnerships. The company is based in Cambridge, Mass., and was founded in 2021. Parallel Bio developed an immune organoid platform that combines immune organoids, machine learning, and robotics to model human immune responses at population scale. The company says its platform can produce antibodies against any disease target in 21 days and has discovered eight human high‑affinity antibodies for cancer and infectious diseases. Parallel validated reproducible modeling across diverse patient backgrounds, built a large proprietary biobank, filed IP on key technologies, and demonstrated high‑throughput vaccine response screening. It plans to bring the immune platform to market with pharmaceutical and biotechnology partners to accelerate drug discovery and reduce reliance on animal testing. The company raised a $4.3 million seed round to accelerate commercialization and proof‑of‑concept work. Parallel positions its technology as able to shift drug development outcomes (claiming it can flip a 95% clinical‑trial failure rate toward success) and to enable discovery of organoid‑derived therapeutics and autoimmune disease models.

Total raised

$25M

Funding rounds

2

Latest round

Series A

Latest activity

Jun 2025